R2 Innovations, LLC was founded by Robert L. Senter and Robert E. Matuszewski in 1998, a privately owned, Colorado based, Limited Liability Company. Sievers Biotech joined the company in 2016 adding new technologies to transition R2’s cannabidiol and cannabis oils into an extremely fine dry powder for deep lung inhalation supported by US Patent Application, 20160228385. The combined talents of Sievers Biotech with the support of its analytical chemist, engineers and advanced technologies allows development and testing of the 1st CBD / cannibals powdered metered dose inhaler directed at the treatment of asthma, a common chronic inflammatory disease of the airways and other pulmonary diseases
R2’s MISSION is to be recognized as a worldwide leader in natural remedies and prescription cannabidiol pharmaceutical medicines directed at specific ailments supported by independent clinical studies and protected by US patents.
R2's VISION is to lead the global marketplace in advanced alternative medications with emphasis on respiratory therapies, supported by; clinical research, double blind studies, duplicated independent lab testing and supported by R2’s proprietary cannabidiol medicines/formulations utilizing chosen delivery systems that eliminate the adverse side effects of current synthetic medications.